Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL180801 | 0.77 | ALDH1A1 (0.58) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| Bromide SCHEMBL28502656 | 0.76 | LMNA (0.55) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL394346 | 0.75 | ALDH1A1 (0.63) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| Bromide SCHEMBL5208416 | 0.75 | ALDH1A1 (0.53) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL37382 | 0.74 | ALDH1A1 (0.68) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL78553 | 0.74 | ALDH1A1 (0.68) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL30001820 | 0.74 | ALDH1A1 (0.68) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| SCHEMBL27144 | 0.74 | ALDH1A1 (0.68) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6224233 | 0.74 | MEN1 (0.51) | ALDH1A1TDP1KMT2AL3MBTL1LMNA | |
| SCHEMBL14066236 | 0.74 | ALDH1A1 (0.61) | ALDH1A1TDP1KMT2AMAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | SHIONOGI & CO., LTD (JP) | 2012-11-01 | — | — | US | disclosed |
| EP-2460794-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | Shionogi & Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457205-A1 | ANGIOGENESIS INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | ALDH1A1 1014/4885TDP1 4769/4885KMT2A 4200/4885 |
| US-20120277238-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE | HRH4, HRH3, HRH2 | ALDH1A1 4042/4885TDP1 4416/4885KMT2A 1077/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | ALDH1A1 1011/4885TDP1 4793/4885KMT2A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.